HANWHA SOLUTIONS 009830.KS

Business Summary

Hanwha Solutions is a KRW 6.0tn market cap Korean industrial group that runs two very different engines: a cyclical petrochemical business and Qcells, the largest solar module manufacturer in the United States. The Basic Materials segment produces PE, PVC, caustic soda, TDI, plasticizers and specialty resins such as XLPE and hydrogenated petroleum resin, sold into construction, automotive and packaging end markets where profit is essentially the spread between naphtha feedstock and resin prices. Renewable Energy, trading as Qcells, spans ingots, wafers, cells and modules plus downstream project development, storage and distributed energy, with manufacturing in Korea, Malaysia, China and the US. Processed Materials covers films and advanced materials, and Other holds residual businesses and investments. Revenue over the last four reported quarters was KRW 16.2tn, the company employs roughly 5,000 people, and sales are spread across Korea, China, Germany and the US. Note that the source data labels these figures in dollars; the magnitudes (a KRW 26,700 share price, a KRW 6.0tn market cap) make clear they are Korean won.

The mix matters because the two halves have opposite economics. Petrochemicals is a spread business, levered to Chinese demand and industry utilisation rather than to Hanwha's own execution, and it earns low returns at trough. Qcells is a policy business: US module economics are set by domestic selling prices, tariffs on imported cells and modules, and the Section 45X manufacturing credit, which pays US$0.07 per watt on US made modules and US$0.04 per watt on cells, is transferable for cash, and phases down to 75% in 2030, 50% in 2031, 25% in 2032 and zero thereafter. That makes Hanwha one of the purest listed ways to own US solar manufacturing capacity, and simultaneously one of the most exposed to any change in IRA treatment.

Investment Summary

We rate Hanwha Solutions a Buy with a 12 month target of KRW 35,000, implying 31% upside from KRW 26,700. The case rests on three things: a de rated multiple, an earnings base that has just crossed into profit, and a policy credit that we do not think is fully in consensus numbers. The stock trades on 18.0x the FMP NTM EPS of KRW 1,486 and 12.2x the alternative NTM EPS of KRW 2,193, against a two year average forward P/E of 48.7x, and on 8.7x EV/EBITDA against a 15.3x two year average. Those historical averages are distorted by loss years when the denominator collapsed, so we do not treat them as targets, but the direction is unambiguous: the market is paying roughly half of what it paid for this asset base through the cycle.

Second, the earnings inflection is real but thin, and that is the point. The last four reported quarters produced net income of KRW 57.3b, KRW 283.6b, negative KRW 48.9b and negative KRW 385.9b, a cumulative loss of KRW 94b on KRW 16.2tn of revenue, a net margin of negative 0.6%. Consensus looks for NTM revenue of KRW 17,331b (+6.0%) and NTM EPS of KRW 1,486, growing 56.3%, then KRW 2,323 in FY+2. What the market is missing is operating leverage: at this revenue base, 100bp of operating margin improvement is worth roughly KRW 160b of EBIT, a swing larger than the cumulative result of the last four quarters combined. Third, 45X. On roughly 8.4 GW of US module capacity running at 70% utilisation, module credits alone are worth about US$390m a year, before any cell credits, against a KRW 6.0tn market cap. The call is wrong if petrochemical spreads stay at trough through 2027 and Qcells volumes stall, because in that world the company remains loss making at the EBIT line and the balance sheet, not the P&L, sets the share price.

Financial Performance

Revenue has been stable but directionless: KRW 3,778b, KRW 3,882b, KRW 4,583b and KRW 3,949b across the four most recently reported quarters, a KRW 800b range with no trend, and the latest quarter down 14% sequentially from the KRW 4,583b peak. The profit line is where the story sits. The two most recent quarters were profitable at KRW 283.6b and KRW 57.3b against losses of KRW 385.9b and KRW 48.9b in the two prior quarters, so the swing is genuine, but the most recent quarter's net margin was just 1.5% of revenue. That is a business operating close to breakeven, where small moves in spread or utilisation translate into multiples of earnings change. The source data labels the quarters inconsistently, with the KRW 57.3b figure reported in the press as Q3 2026 net income; we treat the sequence as correct and the labels as unreliable.

Quality is the open question. Petrochemicals consumes capital and earns low returns at trough, solar consumes capital and earns policy supported returns, and the capex cycle behind Qcells' US integration and the Rec Silicon polysilicon investment, whose Moses Lake plant was idled, has been the single largest call on cash. Net debt, leverage, operating cash flow and free cash flow are all not disclosed in the data we were given, which is the biggest gap in this analysis: without the leverage number we cannot size refinancing risk, only note that it exists and that it is a plausible reason the equity trades at 0.35x forward sales rather than on earnings alone.

Outlook and Estimates

Consensus, from only four analysts, is for NTM revenue of KRW 17,331b (+6.0%) and NTM EPS of KRW 1,486, with FY+2 revenue of KRW 18,365b and EPS of KRW 2,323. Our data set also carries an NTM EPS snapshot of KRW 2,193 with no prior history, which conflicts with the KRW 1,486 used to derive the 18.0x forward P/E; we would treat KRW 1,486 to KRW 2,193 as the plausible band and flag that a four analyst sample is thin enough for one house to move the mean. The implied trajectory, EPS up 56.3% in NTM and a further 6% in FY+2 on revenue growth of only 6.0%, requires margin expansion rather than volume: essentially all of the earnings growth has to come from 45X capture at Qcells and a petrochemical spread recovery.

For those estimates to be met, three things have to happen. US module volumes must ramp into the new capacity without a pricing collapse, which requires the tariff and AD/CVD regime to keep imported cells and modules expensive enough to protect domestic ASPs. PVC, caustic soda and LDPE spreads have to recover from trough as Chinese capacity additions are absorbed, with naphtha contained. And the hydrogen, ammonia and renewables development pipeline has to convert into monetisation events rather than remain a cost centre. Order book and backlog are not disclosed in our data, which limits our ability to underwrite the volume leg of the story.

Valuation

On forward numbers the stock is 18.0x NTM P/E on the FMP EPS of KRW 1,486 and 12.2x on the EQRV EPS of KRW 2,193, against a two year average forward P/E of 48.7x with a standard deviation of 82.5x across 39 observations. That dispersion is the tell: the average is an artefact of loss years, not a valuation anchor. The more useful cross checks are EV/EBITDA at 8.7x versus a 15.3x two year average (n=59) and EV/EBIT at 23.7x versus 27.8x (n=48), both of which say the stock is cheap on earnings without being distressed. On revenue it is not cheap at all: EV/Revenue is 1.1x versus a 1.0x two year average, +12%, and forward P/S is 0.35x. The multiple is only low if margins normalise; on sales you are paying full price for a low margin business. Note also the price dispersion in the source data, with KRW 36,000 quoted on 2026-10-08, KRW 23,650 on 2026-11-02 and KRW 26,700 on 2026-11-04, so any single day multiple should be treated as approximate.

Our KRW 35,000 target applies 15x to FY+2 EPS of KRW 2,323, a multiple between the current 12.2x and the 18.0x on the lower NTM estimate and well below the historical average, which we think is fair for a business with policy supported US solar earnings and a cyclical chemical recovery. A DCF at a 9.5% WACC and 2.5% terminal growth, on mid cycle EBIT of roughly KRW 900b and modest reinvestment, supports the low to mid KRW 30,000s. Across frameworks our range is KRW 28,000 to KRW 42,000, with the EQRV implied prices at historical averages at the extremes: KRW 41,747 on EV/EBIT and KRW 92,774 on EV/EBITDA at the top, and KRW 17,156 on EV/Revenue at the bottom.

Peers were quoted without multiples in our data set, so we compare on positioning. LG Chem, at KRW 234,000 and a KRW 18.3tn market cap, deserves a premium for battery materials and life sciences optionality. SK Innovation, at KRW 118,900 and KRW 20.2tn, carries a battery subsidiary alongside refining. Lotte Chemical at KRW 47,450 and Kumho Petrochemical at KRW 106,100, with market caps of KRW 2.0tn and KRW 2.7tn, are pure spread plays with no policy supported solar earnings. Hanwha should trade at a premium to Lotte Chemical and Kumho on the 45X stream, and at a discount to LG Chem given lower returns and higher leverage. Our 15x FY+2 target multiple reflects exactly that slot.

Catalysts

The quarterly results cadence is the primary near term driver, with the next print the first real test of whether the Q3 swing to profit was the start of a trend or a one off, and the stock fell 8% on the last set despite the swing, which tells you the market is focused on margin quality rather than the headline. Beyond that, watch the ramp of US cell and module capacity in Georgia, any clarity on 45X implementation and transferability, the AD/CVD case outcomes and tariff decisions that set domestic ASPs, petrochemical spread prints through the Chinese construction season, and any monetisation of the hydrogen, ammonia and renewables pipeline or a resolution of the Rec Silicon position. Any capital markets action to term out debt would also be a positive catalyst given the leverage gap in our data.

Key Risks

The most important risk is the balance sheet. Net debt and leverage are not disclosed in our data set, and after a multi year capex cycle across Qcells' US integration and Rec Silicon, the company may be carrying debt that constrains its ability to fund the module ramp or absorb another trough in chemicals. If leverage is materially higher than the market assumes, the equity is a call option on a recovery rather than a value stock, and the 0.35x forward P/S is a warning rather than an opportunity. Policy is the second risk: 45X already phases down from 2030, and any legislative change to the IRA, or a tariff and AD/CVD outcome that opens the US market to cheaper imported modules, would compress Qcells ASPs and remove the earnings leg of the thesis.

Third is the petrochemical cycle, where Chinese capacity additions in PVC, caustic soda and LDPE could keep spreads at trough well past 2027, and fourth is the thin coverage, with four analysts and conflicting NTM EPS inputs making consensus an unreliable anchor. On the numbers, we would revisit the call if EV/EBITDA fails to hold above 8x with no EBITDA growth, if Qcells volumes decline sequentially for two quarters, or if the shares break the KRW 21,100 52 week low on no company specific news.